Know Cancer

or
forgot password

Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry


N/A
N/A
N/A
Open (Enrolling by invite only)
Both
Diabetes, Diabetes Mellitus, Type 2, Medullary Thyroid Carcinoma

Thank you

Trial Information

Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry


Inclusion Criteria:



- A record of medullary thyroid carcinoma (MTC) identified from state/regional
population-based cancer registries

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

Annual incidence of MTC in the US to identify any possible increase related to the introduction of liraglutide and other GLP-1 analogs into the US market

Outcome Time Frame:

December 2011 to December 2025

Safety Issue:

No

Principal Investigator

Paula M. Hale

Investigator Role:

Study Director

Investigator Affiliation:

Novo Nordisk

Authority:

United States: Food and Drug Administration

Study ID:

NN2211-3965

NCT ID:

NCT01511393

Start Date:

January 2012

Completion Date:

December 2025

Related Keywords:

  • Diabetes
  • Diabetes Mellitus, Type 2
  • Medullary Thyroid Carcinoma
  • Carcinoma
  • Thyroid Neoplasms
  • Diabetes Mellitus
  • Diabetes Mellitus, Type 2
  • Thyroid Diseases

Name

Location

Novo Nordisk Clinical Trial Call CenterBerlin, New Jersey  08009